Search Results

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24

Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project Officially Launched

On August 22, the groundbreaking ceremony for the Hengyang New Radiopharmaceutical Isotope and Drug Industrialization Project was held in Hengyang, Hunan Province. Officials from Hengyang City and Zhuhui District, representatives from relevant colleges of the University of South China, investment institutions, and relevant personnel from New Radiopharmaceutical Medical attended the event. Cai Jiming, Chairman and President of New Radiopharmaceutical Medical, stated at the ceremony that the project's landing in Hengyang represents an important strategic layout for the company's nuclear medicine business. From contract signing to construction commencement, the project has received support from local governments, partners, and relevant organizations. The company will leverage this project as an opportunity to continue advancing the transformation of innovative achievements in the fields of medical isotopes and radiopharmaceuticals. Wang Jing, Deputy Mayor of Hengyang City, stated that Hengyang...

2026-08-22

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange

On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...

2026-08-21

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

Indonesia's BRIN Showcases Nuclear Technology Research Progress, Covering Radiopharmaceuticals and Food Irradiation Applications

The National Research and Innovation Agency (BRIN) of Indonesia recently showcased its nuclear technology research achievements at the Presidential Palace in Jakarta. BRIN Head Arief Satria stated that the relevant technologies fall within the scope of peaceful uses of nuclear energy, with applications extending beyond energy to also cover food and health sectors. In the health sector, BRIN is developing radiopharmaceuticals for nuclear medicine. These drugs contain radioactive substances and can be used for cancer diagnosis and treatment. Arief stated that radiopharmaceutical research and development is of great significance for cancer detection and therapy. In the food sector, BRIN applies nuclear technology to food preservation, with a focus on irradiation treatment of export fruits. Arief explained that some importing countries re...

2026-08-07

Zhang Yiming, Chairman of HTA: Tackling the "Last Mile" of Nuclear Pharmacy Network Delivery to Bring Domestic Radiopharmaceuticals to Patients in Western and County-Level Regions

On July 28, the 2026 Radiopharmaceutical Innovation and Development Conference was held in Taiyuan, Shanxi Province. Zhang Yiming, Party Committee Secretary and Chairman of HTA, told reporters that the company is restructuring its short half-life radiopharmaceutical delivery system through "regional layout + standardized logistics + grassroots empowerment," striving to ensure that cancer patients in western and county-level regions can access domestically produced radiopharmaceuticals within the drug's effective half-life window. Currently, multi-dimensional policy dividends are being continuously released, and China's radiopharmaceutical industry is entering a critical window of opportunity. Alpha nuclide drugs represent the future direction of therapeutic radiopharmaceuticals. Zhang Yiming introduced that HTA has already made early arrangements for drug research in this field, jointly conducting research on actinium-225 labeled...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04